Feb 9, 2026 07:30AM
Jan 20, 2026 06:41AM
Jan 6, 2026 07:30AM
Jan 6, 2026 07:30AM
Nov 14, 2025 07:31AM
Nov 14, 2025 07:30AM
Nov 14, 2025 07:30AM Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
Mar 31, 2025 06:43AM
Jul 29, 2024 07:15AM
Jul 28, 2024 05:00PM
Jul 28, 2024 05:00PM
Jul 22, 2024 07:01AM
May 22, 2024 07:37AM
May 22, 2024 07:30AM Anavex Life Sciences Announces Expansion of Leadership Team
May 9, 2024 07:30AM
Apr 29, 2024 07:15AM
Apr 22, 2024 01:45AM
Apr 20, 2024 09:00PM
Apr 16, 2024 09:00PM
Apr 15, 2024 11:15AM
Apr 12, 2024 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
Apr 1, 2024 11:30AM
Mar 25, 2024 12:30PM
Mar 18, 2024 12:30PM
Mar 18, 2024 07:30AM
Mar 14, 2024 12:30PM
Feb 7, 2024 07:30AM
Jan 16, 2024 07:31AM Anavex Life Sciences (AVXL) Announces Phase 2 Trial of ANAVEX3-71 in Schizophrenia
Jan 16, 2024 07:30AM
Jan 2, 2024 08:01AM
Jan 2, 2024 08:00AM
Nov 6, 2023 08:00AM
Jun 28, 2023 07:30AM
Jun 28, 2023 07:30AM
Jun 12, 2023 07:30AM Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ
Jun 6, 2023 07:30AM
May 9, 2023 07:30AM
Mar 9, 2023 07:00AM
Feb 2, 2023 07:00AM
Nov 28, 2022 07:00AM
Nov 7, 2022 07:04AM
Nov 7, 2022 07:00AM Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome
Aug 9, 2022 07:00AM
Aug 2, 2022 07:04AM
Aug 2, 2022 07:00AM
May 10, 2022 07:00AM
Feb 11, 2022 09:00PM
Feb 10, 2022 08:29AM
Feb 9, 2022 07:00AM Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 First Quarter Financial Results
Feb 4, 2022 07:01AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All